Non-Alcoholic Steatohepatitis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Viking Therapeutics, AstraZeneca, Oramed Pharma.
| Published date | 03 April 2024 |
M2 PRESSWIRE-April 3, 2024-: Non-Alcoholic Steatohepatitis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Viking Therapeutics, AstraZeneca, Oramed Pharma
(C)1994-2024 M2 COMMUNICATIONS
RDATE:03042024
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Non-Alcoholic Steatohepatitis pipeline constitutes 100+ key companies continuously working towards developing 110+ Non-Alcoholic Steatohepatitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Non-Alcoholic Steatohepatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Non-Alcoholic Steatohepatitis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Alcoholic Steatohepatitis Market.
Some of the key takeaways from the Non-Alcoholic Steatohepatitis Pipeline Report:
*Companies across the globe are diligently working toward developing novel Non-Alcoholic Steatohepatitis treatment therapies with a considerable amount of success over the years. *Non-Alcoholic Steatohepatitis companies working in the treatment market are Gmax Biopharm, Lin Biosciences, Viking Therapeutics, Seal Rock Therapeutics, AstraZeneca, Boehringer Ingelheim, Oramed Pharmaceuticals, ENYO Pharma, Terns Pharmaceuticals, NovoNordisk, Madrigal Pharmaceuticals, Inventiva Pharma, and others, are developing therapies for the Non-Alcoholic Steatohepatitis treatment
*Emerging Non-Alcoholic Steatohepatitis therapies in the different phases of clinical trials are- GMA-107, LBS-009, VK-1430, SRT-015, AZD 2693, BI 456906, ORMD-0801, EYP001, TERN-501, Semaglutide, Resmetirom, Lanifibranor, and others are expected to have a significant impact on the Non-Alcoholic Steatohepatitis market in the coming years. *In March 2024, Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical firm specializing in innovative therapies for nonalcoholic steatohepatitis (NASH), has disclosed today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Rezdiffra (resmetirom). This approval is for its use alongside diet and exercise in the treatment of adults diagnosed with noncirrhotic NASH with moderate to advanced liver fibrosis (corresponding to stages F2 to F3 fibrosis). The continuation of approval for this indication may be subject to confirmation and delineation of clinical benefits in ongoing confirmatory studies. *In April 2023, Resmetirom has been...
To continue reading
Request your trial